Kymera Therapeutics Inc (KYMR NASDAQ) stock market data APIs
$45.8352
1.23(2.7%)
as of July 18, 2025
Try our APIs with
free plan!
Kymera Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Prev. Close
45.8352
Open
47.0688
High
47.5584
Low
46.4406
52 wk Range
19.445-53.27
Market Cap
3 252 M
Shares Outstanding
70 157 K
Revenue
58 885 K
EPS
-0.82
Beta
2.074
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kymera Therapeutics Inc data using free add-ons & libraries
Get Kymera Therapeutics Inc Fundamental Data
Kymera Therapeutics Inc Fundamental data includes:
- Net Revenue: 58 885 K
- EBITDA: -271 670 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kymera Therapeutics Inc News
New
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe. T...
Gilead sees Q2 EPS hit from IPR&D expenses
[Gilead corporate headquarters in Silicon Valley] Sundry Photography * Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) said that its Q2 financial results will be negatively imp...
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock ...
Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
There’s no doubt about it: the stock market’s strong performance over the past few months is fueling an optimistic mood. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
